|
Recorded Presentation from Optimizing Patient Outcomes - The Role of Immunotherapy and Emerging Strategies for High-Risk Neuroblastoma |
1.00 |
11/05/2025 - 12:00am to 10/29/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Breast Cancer, Version 5.2025 |
1.00 |
11/10/2025 - 12:00am to 11/10/2026 - 11:59pm |
|
Evolving Treatment Strategies for Acute Myeloid Leukemia |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Monitoring Toxicities in the Ambulatory Setting |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
NCCN Tumor Boards: Optimizing Treatment of Chronic Phase Chronic Myeloid Leukemia |
1.00 |
11/25/2025 - 12:00am to 05/17/2026 - 12:00am |
|
Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma |
1.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment |
2.00 |
12/19/2025 - 12:00am to 06/18/2026 - 11:59pm |
|
NCCN 2026 Oncology Fellows Program: New Horizons in Quality Cancer Care |
5.50 |
04/20/2026 - 12:00am to 07/01/2026 - 12:00am |
|
NCCN 2025 Annual Congress: Hematologic Malignancies™ |
14.50 |
10/11/2025 - 11:30am to 05/31/2026 - 11:59pm |
|
NCCN 2026 Annual Conference: Virtual Attendance |
16.25 |
03/29/2026 - 10:30am to 06/30/2026 - 11:59pm |
|
NCCN 2026 Annual Conference: In-Person Attendance |
20.25 |
03/29/2026 - 10:30am to 06/30/2026 - 11:59pm |
Facebook
X
LinkedIn
Forward